Linked Life Data

17194716

Source:http://linkedlifedata.com/resource/pubmed/id/17194716

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17194716rdf:typepubmed:Citationlld:pubmed
pubmed-article:17194716lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:17194716lifeskim:mentionsumls-concept:C2936803lld:lifeskim
pubmed-article:17194716lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:17194716lifeskim:mentionsumls-concept:C0887819lld:lifeskim
pubmed-article:17194716lifeskim:mentionsumls-concept:C0450363lld:lifeskim
pubmed-article:17194716pubmed:issue3lld:pubmed
pubmed-article:17194716pubmed:dateCreated2007-2-27lld:pubmed
pubmed-article:17194716pubmed:abstractTextCYP51 fulfills an essential requirement for all cells, by catalyzing three sequential mono-oxidations within the cholesterol biosynthesis cascade. Inhibition of fungal CYP51 is used as a therapy for treating fungal infections, whereas inhibition of human CYP51 has been considered as a pharmacological approach to treat dyslipidemia and some forms of cancer. To predict the interaction of inhibitors with the active site of human CYP51, a three-dimensional quantitative structure-activity relationship model was constructed. This pharmacophore model of the common structural features of CYP51 inhibitors was built using the program Catalyst from multiple inhibitors (n = 26) of recombinant human CYP51-mediated lanosterol 14alpha-demethylation. The pharmacophore, which consisted of one hydrophobe, one hydrogen bond acceptor, and two ring aromatic features, demonstrated a high correlation between observed and predicted IC(50) values (r = 0.92). Validation of this pharmacophore was performed by predicting the IC(50) of a test set of commercially available (n = 19) and CP-320626-related (n = 48) CYP51 inhibitors. Using predictions below 10 microM as a cutoff indicative of active inhibitors, 16 of 19 commercially available inhibitors (84%) and 38 of 48 CP-320626-related inhibitors (79.2%) were predicted correctly. To better understand how inhibitors fit into the enzyme, potent CYP51 inhibitors were used to build a Cerius(2) receptor surface model representing the volume of the active site. This study has demonstrated the potential for ligand-based computational pharmacophore modeling of human CYP51 and enables a high-throughput screening system for drug discovery and data base mining.lld:pubmed
pubmed-article:17194716pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17194716pubmed:languageenglld:pubmed
pubmed-article:17194716pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17194716pubmed:citationSubsetIMlld:pubmed
pubmed-article:17194716pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17194716pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17194716pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17194716pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17194716pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17194716pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17194716pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17194716pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17194716pubmed:statusMEDLINElld:pubmed
pubmed-article:17194716pubmed:monthMarlld:pubmed
pubmed-article:17194716pubmed:issn0090-9556lld:pubmed
pubmed-article:17194716pubmed:authorpubmed-author:EkinsSeanSlld:pubmed
pubmed-article:17194716pubmed:authorpubmed-author:TreadwayJudit...lld:pubmed
pubmed-article:17194716pubmed:authorpubmed-author:HarwoodH...lld:pubmed
pubmed-article:17194716pubmed:authorpubmed-author:HooverDennis...lld:pubmed
pubmed-article:17194716pubmed:authorpubmed-author:MankowskiDayn...lld:pubmed
pubmed-article:17194716pubmed:authorpubmed-author:LawtonMichael...lld:pubmed
pubmed-article:17194716pubmed:issnTypePrintlld:pubmed
pubmed-article:17194716pubmed:volume35lld:pubmed
pubmed-article:17194716pubmed:ownerNLMlld:pubmed
pubmed-article:17194716pubmed:authorsCompleteYlld:pubmed
pubmed-article:17194716pubmed:pagination493-500lld:pubmed
pubmed-article:17194716pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:17194716pubmed:meshHeadingpubmed-meshheading:17194716...lld:pubmed
pubmed-article:17194716pubmed:meshHeadingpubmed-meshheading:17194716...lld:pubmed
pubmed-article:17194716pubmed:meshHeadingpubmed-meshheading:17194716...lld:pubmed
pubmed-article:17194716pubmed:meshHeadingpubmed-meshheading:17194716...lld:pubmed
pubmed-article:17194716pubmed:meshHeadingpubmed-meshheading:17194716...lld:pubmed
pubmed-article:17194716pubmed:meshHeadingpubmed-meshheading:17194716...lld:pubmed
pubmed-article:17194716pubmed:meshHeadingpubmed-meshheading:17194716...lld:pubmed
pubmed-article:17194716pubmed:meshHeadingpubmed-meshheading:17194716...lld:pubmed
pubmed-article:17194716pubmed:meshHeadingpubmed-meshheading:17194716...lld:pubmed
pubmed-article:17194716pubmed:year2007lld:pubmed
pubmed-article:17194716pubmed:articleTitleThree-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.lld:pubmed
pubmed-article:17194716pubmed:affiliationComputational Biology, ACT LLC, 601 Runnymede Ave., Jenkintown, PA 19046, USA. ekinssean@yahoo.comlld:pubmed
pubmed-article:17194716pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:17194716lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17194716lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17194716lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17194716lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17194716lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17194716lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17194716lld:pubmed